Abstract. Thymoquinone (TQ), the predominant bioactive constituent derived from the medicinal spice Nigella sativa (also known as black cumin), has been applied for medical purposes for more than 2,000 years. Recent studies reported that thymoquinone exhibited inhibitory effects on the cell proliferation of several cancer cell lines. This study was performed to investigate the antitumor and anti-angiogenic effects of thymoquinone on osteosarcoma in vitro and in vivo. Our results showed that thymoquinone induced a higher percentage of growth inhibition and apoptosis in the human osteosarcoma cell line SaOS-2 compared to that of control, and thymoquinone significantly blocked human umbilical vein endothelial cell (HUVEC) tube formation in a dose-dependent manner. To investigate the possible mechanisms involved in these events, we performed electrophoretic mobility shift assay (EMSA) and western blot analysis, and found that thymoquinone significantly downregulated NF-κB DNA-binding activity, XIAP, survivin and VEGF in SaOS-2 cells. Moreover, the expression of cleaved caspase-3 and Smac were upregulated in SaOS-2 cells after treatment with thymoquinone. In addition to these in vitro results, we also found that thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing NF-κB and its regulated molecules. Collectively, our results demonstrate that thymoquinone effectively inhibits tumor growth and angiogenesis both in vitro and in vivo. Moreover, inhibition of NF-κB and downstream effector molecules is a possible underlying mechanism of the antitumor and anti-angiogenic activity of thymoquinone in osteosarcoma.

Introduction

Osteosarcoma is a primary malignant tumor of the skeleton characterized by the direct formation of immature bone or osteoid tissue by the tumor cells. It is an extremely aggressive malignancy that arises mostly in the long bones (1). Limited improvements have been made by using conventional methods including surgery, radiotherapy and chemotherapy in the past two decades (2). Despite the availability of a myriad of treatment modalities, including preferred cytotoxic chemotherapy, dose-limiting toxicity to normal tissues and acquisition of acquired resistance fails to transcend into optimal clinical benefit in terms of cure rate in an overwhelming majority of patients (3,4). Therefore, there is a need for novel strategies involving less toxic agents for their potential in improving the prognosis and therapy of patients with osteosarcoma.

Thymoquinone (TQ) is the bioactive compound derived from black seed (Nigella sativa) oil. It is an annual herb that grows in countries bordering the Mediterranean region and in Western Asian countries including India, Pakistan, and Afghanistan. In traditional medicine, thymoquinone is known to be the active principle responsible for many of the seed's anti-oxidant and anti-inflammatory effects (5). Numerous studies have shown that the seeds and oil of this plant are characterized by a very low degree of toxicity (6). Regarding cancer, recent studies showed that thymoquinone exerts anti-proliferative and apoptosis-inducing effects on various tumor cells derived from colorectal carcinoma (7), lung carcinoma (8), myeloblastic leukemia (9) and prostate carcinoma (10). Thymoquinone has also been shown to potentiate the anti-tumor activity of gemcitabine and oxaliplatin in pancreatic cancer (11). Mechanistically, thymoquinone has been reported...
to induce apoptosis in tumor cells by suppressing NF-κB, Akt activation, and extracellular signal-regulated kinase signaling pathways and to also inhibit tumor angiogenesis (11-14). Although Roepke et al reported that thymoquinone showed inhibitory effects on human osteosarcoma cells (15), whether thymoquinone inhibits osteosarcoma in vivo and suppresses osteosarcoma growth through tumor angiogenesis prevention remains unclear.

In the present study, we first sought to understand the molecular mechanism of action of thymoquinone in osteosarcoma cells inducing apoptosis and we tested our hypothesis in vivo using an orthotropic model of osteosarcoma. Using in vivo data, we show, for the first time, that thymoquinone exerts antitumor and anti-angiogenesis activity in osteosarcoma. These results are correlated with the downregulation of NF-κB and its downstream proteins such as X-linked inhibitor of apoptosis (XIAP), survivin and vascular endothelial growth factor (VEGF) in tumor extracts.

Materials and methods

Reagents. Antibodies were obtained from the following commercial sources: antibodies against survivin, XIAP, Smac and β-actin were obtained from Epitomics (Burlingame, CA, USA), and the caspase-3 antibody was from Abcam (Cambridge, MA, USA). Anti-retinoblastoma antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Thymoquinone was purchased from Sigma (St. Louis, MO, USA) and was dissolved in DMSO to make 20 mmol/l stock solution. The 0.1% DMSO alone was set as the control group.

Cell culture. Human osteosarcoma cell line SaOS-2 was purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). Mouse osteoblastic cell line MC3T3-E1 was preserved in our laboratory. SaOS-2 and MC3T3-E1 cells were maintained in modified Eagle’s medium containing 10% fetal bovine serum (FBS), 0.5% penicillin-streptomycin, and 1% glutamine at 37°C with 5% CO₂. Human umbilical vein endothelial cells (HUVECs; obtained from ATCC) were cultured in gelatin-coated plates with M199 medium containing 20% FBS, endothelial cell growth supplement (50 µg/ml, Sigma) and antibiotics, and incubated at 37°C in 5% CO₂ in air.

Hoechst 33342 staining for apoptotic nuclei. Morphological changes of SaOS-2 cells were observed under a fluorescence microscope (Olympus, Tokyo, Japan) by the Hoechst staining method. SaOS-2 cells were seeded at a density of 2x10⁵ cells per well onto a 12-well plate for 24 h, followed by incubation with vehicle alone (0.1% DMSO) or 80 µmol/l thymoquinone for 24 h. Following treatment, cells were fixed with 3.7% formaldehyde for 15 min, permeabilized with 0.1% Triton X-100 and stained with 5 µg/ml of Hoechst 33258 for another 5 min at 37°C. The cells were then washed with PBS and observed under a fluorescence microscope.

Cell viability inhibition by thymoquinone. SaOS-2 cells were seeded at a density of 3x10⁴ cells per well in 96-well culture plates. After overnight incubation, the medium was removed and replaced with fresh medium containing different concentrations of thymoquinone (20, 40 and 80 µmol/l). Following a 24-h incubation, cell viability was determined by CCK-8 assay (Dojin Laboratory, Kumamoto, Japan) according to the manufacturer’s instructions. Briefly, CCK-8 solution was added to cells in 96-well plates, the cells were then incubated at 37°C for 60 min, and absorbance was measured at 570 nm using an MRX Revelation 96-well multisecner (DynaTec Technologies, Chantilly, VA, USA). This experiment was repeated three times.

Flow cytometric assessment of apoptosis. The measurement of phosphatidylserine redistribution in a plasma membrane was conducted according to the protocol outlined by the manufacturer of the Annexin V-FITC/PI apoptosis detection kit (Abcam). After exposing the cells to increasing concentrations of thymoquinone (20, 40 and 80 µmol/l) for 24 h at 6-well plates, harvested 1x10⁵ cells were incubated with 5 µl of Annexin V-FITC and 5 µl of PI for 15 min at room temperature in the dark and then analyzed by flow cytometry using the Cell Quest program (Becton-Dickinson, San Jose, CA, USA).

Tube formation assay. The angiogenesis of HUVEC induced by Matrigel was assessed by the modified methods previously described (12). Briefly, Matrigel (Becton-Dickinson) was dissolved at 4°C overnight, and each well of pre-chilled 48-well plates was coated with 100 µl Matrigel and incubated at 37°C for 45 min. HUVECs (2x10⁴ cells) were seeded onto the Matrigel in 250 µl M199 supplemented with 20% FBS and incubated with various concentrations of thymoquinone (40, 80 and 160 nmol/l) at 37°C for 24 h in a humidified 5% CO₂ atmosphere. Endothelial cell tube formation was photographed and the light micrograph images were stored in a computer. Tubular structures were quantified by manual counting and percent inhibition was expressed using untreated wells as 100%.

Western blot analysis. At the end of this incubation, cells were washed with ice-cold PBS and lysed in NP40 lysis buffer (20 mmol/l Tris-HCl (pH 7.4), 100 mmol/l NaCl, 1% NP40, 0.5% sodium deoxycholate, 5 mmol/l MgCl₂, 0.1 mmol/l phenylmethylsulfonyl fluoride, and 10 mg/ml of protease inhibitor mixture). Protein was extracted using Mammalian Protein Extraction Reagent (Pierce Inc., Rockford, IL, USA) and its concentration was determined by BCA (Pierce) assay. Western blot analysis was conducted according to the protocol outlined by the manufacturer (Pierce). Briefly, Matrigel (Becton-Dickinson) and its concentration was determined by BCA (Pierce) assay. Proteins (30 µg) were separated in 10-15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane. Membranes were incubated with primary antibody overnight at 4°C and then with the respective secondary antibodies. Immunoreactive bands were detected by the enhanced chemiluminescence (ECL) kit for western blotting detection with hyper-ECL film. The same membrane was reprobed with the anti-β-actin antibody, which was used as an internal control for protein loading.

Electrophoretic mobility shift assay. Following treatment, the cells were suspended in 400 µl of ice-cold lysis buffer [1 mol/l HEPES (pH 7.9), 1 mol/l KCl, 0.5 mol/l EDTA, 0.1 mol/l EGTA, 0.1 mol/l DTT, 0.1 mol/l PMSP, 2 µg/ml aprotinin, 2 µg/ml leupeptin, and 0.5 mg/ml benzamidin] for 15 min. The cells were allowed to swell on ice for 20 min and then 4.8 µl of 10% Nonidet P-40 was added to every 400 µl cell
suspension, vortexed, and centrifuged for 1 min at 4°C. The nuclear pellet was resuspended in 30 µl nuclear extraction buffer [2 mol/l HEPES (pH 7.9), 0.4 mol/l NaCl, 1 mol/l EDTA, 0.1 mol/l EGTA, 0.1 mol/l DTT, 0.1 mol/l PMSF, 2 µg/ml aprotinin, 2 µg/ml leupeptin, and 0.5 mg/ml benzamidine] and incubated on ice with intermittent mixing. The tubes were then centrifuged at 10,000 g for 20 min at 4°C, and the supernatant (nuclear extract) was quantified using the BCA protein assay. Electrophoretic mobility shift assay (EMSA) was performed by incubating 10 µg of nuclear proteins with IRDye™-700 labeled NF-κB oligonucleotide. The incubation mixture included 2 µg of poly(deoxyinosinic-deoxyctydyllic acid) in a binding buffer. The DNA-protein complex formed was separated from free oligonucleotide on 8.0% native polyacrylamide gel using buffer containing 50 mmol/l Tris, 200 mmol/l glycine (pH 8.5), and 1 mmol/l EDTA and then visualized by Imager apparatus. Equal protein loading was ensured by immunoblotting 10 µg of nuclear protein with anti-Rb antibody.

Mouse osteosarcoma models and experimental protocol. Male athymic BALB/c nu/nu mice (4–6 weeks old) were obtained from Wenzhou Medical College. All animals were maintained in the standard mouse plexiglass cages in a room maintained at constant temperature and humidity under 12-h light and darkness cycle. The food, water, and bedding for these immunocompromised mice were sterilized and changed at least once weekly.

The spontaneously metastatic mouse model was developed as previously described (16). Briefly, the left tibia was wiped with 70% ethanol and a 27-gauge needle coupled to a Hamilton syringe was inserted into the tibial plateau with the knee flexed, and 1x10⁶ SaOS-2 cells, resuspended in 10 µl PBS, were injected into the marrow space of the proximal tibia. As a control, all animals were injected with contorted 0.1% DMSO in the contralateral tibia. After 1 week of implantation, mice were randomized into 2 groups (n=6): a) vehicle alone (control); b) thymoquinone (6 mg/kg given daily by intragas syringe was inserted through the tibial plateau with the knee flexed, and 1x10⁶ SaOS-2 cells, resuspended in 10 µl PBS, were injected into the marrow space of the proximal tibia. As a control, all animals were injected with contorted 0.1% DMSO in the contralateral tibia. After 1 week of implantation, mice were randomized into 2 groups (n=6): a) vehicle alone (control); b) thymoquinone (6 mg/kg given daily by intragas

Thymoquinone induces cell morphological changes. To further examine the cytotoxic effects of thymoquinone on SaOS-2 cells, the cells were treated with increasing concentrations of thymoquinone (20, 40 and 80 µmol/l) for 24 h, and then the viability of the cells was examined by CCK-8 assays. As shown in Fig. 1B, the viability of SaOS-2 cells was decreased dose-dependently in the presence of thymoquinone.

Detection of apoptosis with Annexin V. To determine whether the induction of cell death by thymoquinone could be linked to apoptosis in SaOS-2 cells, we used a method that allows one to detect concurrently viable, necrotic, early apoptotic and late apoptotic cells based on distinct double-staining patterns with a combination of FITC-conjugated Annexin V and PI.

Results clearly demonstrated that treatment with thymoquinone (Fig. 1C) for 24 h increased the percentage of early apoptotic cells in a dose-dependent manner (Fig. 1D). These data indicate that thymoquinone exerts cytotoxic effects which may be mediated by apoptosis on SaOS-2 cells.

Thymoquinone inhibits tube formation of HUVECs. Since the final event during angiogenesis is the organization of endothelial cells in a three-dimensional network of tube, we performed a tube formation assay to investigate the effect of thymoquinone on the capillary-like structure formation of HUVECs. Endothelial cells plated on Matrigel align themselves forming cords, and the tube-like structure formation...
was maximal within 15 h (Fig. 1E). Treatment of cells with thymoquinone resulted in significant inhibition of tubule formation of HUVECs on Matrigel (Fig. 1F). Our results clearly demonstrate that thymoquinone is effective in controlling the tube formation of endothelial cells in vitro.

**Thymoquinone inhibits nuclear factor-κB DNA-binding activity.** Next, we analyzed whether thymoquinone could abrogate constitutively expressed NF-κB in osteosarcoma cells. SaOS-2 cells were treated with varying doses of thymoquinone (20, 40 and 80 µmol/l) for 24 h and subjected to gel shift assay (EMSA). As shown in Fig. 2A, EMSA revealed that thymoquinone induced a concentration-dependent decrease in NF-κB DNA binding activity in SaOS-2 cells, which was further confirmed by a supershift experiment. These observations provide strong evidence that thymoquinone is effective in downregulating NF-κB DNA-binding activity.

**Thymoquinone inhibits the expression of NF-κB-regulated gene products.** We assessed the expression of the NF-κB-regulated genes XIAP and survivin, the overexpression of which has been linked to tumor survival, chemoresistance, and radioresistance, and VEGF, which plays an important role in angiogenesis. Western blotting revealed that thymoquinone induced a concentration-dependent decrease in the levels of these molecules compared with the control treatment in SaOS-2 cells. Western blotting also showed that thymoquinone increased the expression of caspase-3 and Smac (Fig. 2B).
Thymoquinone inhibits tumor growth in nude mice. For the in vivo experiment, 12 mice were divided into two groups as described in Materials and methods. The results showed that after 15 days of treatment with thymoquinone, thymoquinone did not produce significant non-tumor toxicity in tumor-bearing mice. The average mouse body weight of the control group decreased from 22.28±1.22 to 21.24±1.32 g, whereas that of the thymoquinone-treated group increased from 22±1.5...
to 24.4±1.2 g (Fig. 3C). The slight decrease of the control group is due to the growth of tumors in the xenograft mice. Next, we determined the mean tumor volume immediately following euthanization in all mice. The mean tumor volume was 74±25 mm³ in the treated group, vs 126±41 mm³ in the negative control tumors, resulting in a significant difference of tumor volume in the xenograft model (P<0.05).

**Tumor histology, immunohistochemistry and protein expression in vivo.** H&E evaluation of the tumors from all groups showed high-grade carcinoma associated with tumor apoptosis and necrosis (Fig. 3A). However, there were significant differences in the pattern of necrosis, inflammatory response and fibrosis among the two groups. In the control group, the tumor was largely viable with high mitosis and minimal intratumoral stroma, whereas the peripheral tumor was largely viable and consisted of large nests of neoplastic cells with minimal intratumoral stroma. By contrast, in the group receiving thymoquinone treatment there was marked tumor destruction throughout the entire tumor.

We next examined the expression of the cell proliferation marker Ki-67 and the microvessel density marker CD34 in tumor tissues from the two groups. The results in Fig. 3A showed that thymoquinone significantly downregulated the expression of Ki-67 and CD34 in tumor tissues compared with the control group. For Ki-67, the proliferation index of control was 77.2±5.1%, but the group receiving thymoquinone treatment was 49.3±4.5%. For CD34, the microvessel density was reduced from 192.3±10.2 to 98.6±14.1 after the treatment of thymoquinone. Furthermore, immunohistochemical analysis revealed that the expression of NF-κB was significantly decreased in tumors derived from mice treated with thymoquinone compared with untreated mice. Tumors also revealed downregulation of a few important NF-κB-regulated molecules such as survivin, XIAP and VEGF proteins, which is consistent with our *in vitro* results.

**Discussion**

Successful treatment with chemotherapeutic agents is largely dependent on their ability to trigger cell death in tumor cells. However, despite rapid advances in diagnostic and operative techniques, osteosarcoma remains one of the most challenging human malignancies to treat, which is partly due to the advanced stage of the disease and the de novo chemoresistant behavior to cytotoxic chemotherapeutic agents. Several previous studies demonstrated that certain phytochemicals present in medicinal herbs exert antitumorigenic activity by inducing apoptosis in cancer cells. Thymoquinone has been reported to exert anti-proliferative effects on several cancer cells *in vitro*, which are mediated through the induction of apoptosis (7-11). Thymoquinone also enhanced sensitivity to chemotherapeutic agents in pancreatic and lung cancer (8,11). In this study, we investigated our hypothesis that thymoquinone exerts antitumor effects on human osteosarcoma SaOS-2 cell line proliferation and apoptosis. In agreement with previous studies, we documented that thymoquinone within the range of tested concentrations, is able to directly inhibit cell viability dose-dependently in SaOS-2 cells *in vitro*, and the morphological changes of thymoquinone-treated cells were typical of apoptosis, nuclear condensation, and DNA fragmentation. Furthermore, inhibition of cell growth was correlated with apoptotic cell death. Fluorescence-activated cell sorting (FACS) analysis showed thymoquinone increased the percentages of apoptotic cells in a dose-dependent manner. In agreement with the results of FACS, induced apoptosis by thymoquinone in pancreatic cells was validated by activation of caspase-3 (12). However, the growth of mouse osteoblastic cells did not significantly change by thymoquinone until 80 µmol/l for 24 h. Similar observations have been reported in thymoquinone-treated human pancreatic ductal epithelial cells, suggesting a moderate concentration of thymoquinone does not show cytotoxicity to normal cells. In addition to *in vitro* results, this is the first report to show that thymoquinone is also as an effective antitumor agent in a mouse osteosarcoma model, and significant differences in the percentage of Ki-67-positive cells were noted in tumors derived from the thymoquinone group relative to untreated animals. Our results are consistent with a previous study that no significant variation in body weight was detected in animals after treatment with thymoquinone (12). Taken together, these data suggest that thymoquinone is a potential drug candidate for cancer chemotherapies with low chemotoxic side-effects.

The question remains as to how thymoquinone induces apoptosis in SaOS-2 cells. Emerging evidence has indicated that overexpression of the pro-survival molecules survivin and XIAP, members of the inhibitor of apoptosis protein (IAP) family, are associated with poor prognosis and increased tumor recurrence (17). Recent studies have identified the activation of caspase-3 is blocked by the IAPs (18). However, second mitochondria-derived activator of caspase (Smac) (also known as DIABLO) is released from mitochondria into the cytosol during apoptosis and functions by eliminating inhibitory effects of IAPs on caspase-3 (19,20). Once released from mitochondria upon an apoptotic stimulus, Smac docks to the IAPs via an amino-terminal Reaper motif. This displaces the IAPs from their caspase-binding sites, thereby relieving the block on caspase activation (21). In the present study, we noted that thymoquinone *per se* was effective as a general inducer of apoptosis in SaOS-2 cells by downregulating survivin and XIAP, and upregulating cleaved caspase-3 and Smac. To support our hypothesis, we present evidence documenting a significant reduction of tumors *in vivo* by thymoquinone that was found to be associated with the inhibition of antiapoptotic survivin and XIAP. Thymoquinone was effective in downregulating IAP proteins, survivin and XIAP, not only in osteosarcoma cells *in vitro* but also in preclinical *in vivo* conditions.

Angiogenesis is crucial for the growth of solid tumors not only by supplying oxygen and nutrients for the survival of tumor cells but also by providing the route for metastatic spread. Therefore, angiogenesis has been an attractive target for tumor therapy (22,23). Accumulating evidence has confirmed the expression of VEGF is closely linked with angiogenesis and has validated the theory that inhibition of VEGF is a promising anticancer strategy (24,25). Here, we showed that thymoquinone effectively inhibited human umbilical vein endothelial cell (HUVEC) tube formation. Furthermore, we found that thymoquinone inhibited tumor angiogenesis and prevented osteosarcoma growth in a mouse osteosarcoma model. In agreement with previous studies (12,26), our study
indicates that thymoquinone can effectively suppress angiogenesis both in vitro and in vivo at this experimental condition. Next we showed that thymoquinone downregulated the expression of VEGF both in vitro and in vivo, which provided an explanation for its inhibition of angiogenesis observed in the mouse osteosarcoma model.

Extensive studies have demonstrated that the rapid-acting primary transcription factor nuclear factor-kB (NF-kB) is constitutively active in osteosarcoma cell lines (27). Emerging evidence suggests that the DNA-binding ability of NF-kB has been implicated in survivin and XIAP expression and the regulation of apoptosis in various cancer cells (11,25), which underscores the role of NF-kB activation in mediating chemoresistance and that several conventional cancer chemotherapeutic agents activate NF-kB leading to an unfavorable clinical outcome (11,25). Furthermore, tumor angiogenesis is regulated by numerous NF-kB-regulated gene products, including VEGF and TNF (25,28). Finally, evidence indicates the importance of NF-kB in osteosarcoma and suggests that agents that block NF-kB activation could reduce chemoresistance and angiogenesis in osteosarcoma and may possibly be used as a novel therapeutic regimen for osteosarcoma. Previous studies have demonstrated that curcumin (25), genistein (29) and hyperthermia (30) exert antitumor and anti-angiogenesis activity through downregulation of NF-kB. In the present study, we found that thymoquinone abrogates NF-kB activation in osteosarcoma SaOS-2 cells. In addition, our in vitro results showed that thymoquinone treatment inhibits NF-kB and exerts anti-proliferative and apoptosis-inducing effects in SaOS-2 cells, suggesting that inhibition of NF-kB by thymoquinone is mechanistically associated with sensitization of osteosarcoma cells to apoptosis. However, most importantly, these in vitro results, such as the antitumor activity and inactivation of NF-kB, were recapitulated in vivo using the mouse osteosarcoma model, which provides a scientific rationale for the therapeutic exploitation of our strategy for the treatment of patients with osteosarcoma. These results provide strong molecular in vitro and in vivo evidence supporting our hypothesis that inactivation of the NF-kB signaling pathway by thymoquinone is likely to be an important and novel strategy for the treatment of osteosarcoma.

In conclusion, our present findings are consistent with the hypothesis that thymoquinone could downregulate antiapoptotic and angiogenesis proteins that are regulated by NF-kB, resulting in loss of osteosarcoma cells to survival. Our in vitro findings are consistent with the in vivo results and provide support for the further development of thymoquinone as an adjunct to conventional chemotherapeutics by targeted inactivation of NF-kB for the treatment of human osteosarcoma, and the initiation of clinical trials.

Acknowledgements

The authors thank all the staff in the Laboratory of Orthopaedic Research Institute and Scientific Research Center of the Second Affiliated Hospital of Wenzhou Medical College. This study was supported by grants from the National Natural Science Foundation of China (31060135/C100302), Project of Science and Technology Department of Zhejiang Province (2010C34006/2010C34G2090013), Project of Health Department in Hainan Province (No.2011-34) and Science-Technology Hall of Hainan Province (GJXM201102).

References


